RAB11FIP3 Antibody

What is the recommended dilution range for RAB11FIP3 antibody in Western blot applications?

For optimal Western blot (WB) detection of RAB11FIP3, most commercial antibodies recommend a dilution range of 1:200-1:1000. This range provides sufficient sensitivity while minimizing background. For specific applications:

It is crucial to titrate the antibody in each testing system to obtain optimal results, as detection efficiency can vary based on tissue type, fixation method, and protein expression levels .

What tissues show positive detection with RAB11FIP3 antibody?

RAB11FIP3 antibody has demonstrated positive detection in multiple tissue types across species:

For IHC applications with human kidney tissue, antigen retrieval with TE buffer (pH 9.0) is suggested, although alternative antigen retrieval may be performed with citrate buffer (pH 6.0) . This indicates that RAB11FIP3 is expressed in neuronal and renal tissues, making the antibody useful for studies in these physiological systems.

How should cell samples be prepared for RAB11FIP3 immunofluorescence microscopy?

For optimal immunofluorescence detection of RAB11FIP3:

• Fix cells with 4% paraformaldehyde for 15 minutes at room temperature

• Permeabilize with 0.4% saponin

• Block non-specific binding sites with phosphate-buffered saline containing 0.2% bovine serum albumin and 1% fetal bovine serum

• Incubate with RAB11FIP3 primary antibody at the recommended dilution (typically 1:50-1:200)

• Wash extensively before applying secondary antibody

• Mount in appropriate medium such as VectaShield

This protocol has been successfully employed in studies examining RAB11FIP3's role in breast carcinoma cells and is adaptable to various cell types . For imaging, an inverted microscope with appropriate filter sets is recommended, with subsequent image processing using three-dimensional rendering software for optimal visualization of subcellular localization.

What are the critical storage conditions for maintaining RAB11FIP3 antibody activity?

To maintain antibody activity and prevent degradation:

• Store at -20°C in the recommended buffer

• For long-term storage, aliquot to avoid repeated freeze-thaw cycles

• Most commercial preparations are stable for one year after shipment when properly stored

• Antibodies are typically supplied in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3

For 20μl size preparations, note that they often contain 0.1% BSA as a stabilizer . Proper storage is critical for maintaining specificity and sensitivity in experimental applications.

How can RNAi be optimized for RAB11FIP3 knockdown studies?

For effective RAB11FIP3 depletion using siRNA:

• Use validated siRNA sequences targeting different regions of RAB11FIP3 (e.g., FIP3#1: sequence from previous studies or FIP3#2: 5'-aaggcgtgtgctggagctgga-3')

• Transfect using Lipofectamine2000 or similar reagent for >90% transfection efficiency

• Incubate transfected cells for 48-72 hours to achieve optimal protein knockdown

• Confirm knockdown efficiency via Western blotting before proceeding with functional assays

• Include appropriate controls (mock transfection, non-targeting siRNA)

For co-depletion studies with Rab11, combine siRNAs targeting both Rab11a/b and FIP3. This approach has been successfully used to investigate functional relationships between these proteins in membrane trafficking pathways .

What structural features of RAB11FIP3 are critical for Rab11 binding and how can antibodies help study these interactions?

RAB11FIP3's Rab11-binding domain (RBD) encompasses a critical C-terminal region (residues 733-756) with specific structural features:

• The minimal RBD forms a long amphiphilic α-helix that creates a parallel coiled-coil homodimer

• This dimeric structure provides two symmetric interfaces that interact with two Rab11 molecules

• Key residues include:

  • Y737: Critical for hydrophobic interactions with switch 1 region of Rab11

  • D739 and E747: Form essential salt bridges with the switch 2 region

  • M746: Required to fill the characteristic large pocket of Rab11

Mutation studies have shown that Y737S, D739A, E747A, and M746S substitutions abolish Rab11 binding . Antibodies targeting these specific regions can be used in competitive binding assays to disrupt protein-protein interactions or to precipitate complexes for interaction studies.

Antibodies targeting epitopes containing these residues are particularly useful for functional studies of RAB11FIP3-Rab11 interaction .

How can RAB11FIP3 antibodies be used to investigate its role in ciliary targeting mechanisms?

To study RAB11FIP3's function in ciliary membrane targeting:

• Immunoprecipitation with RAB11FIP3 antibodies can detect protein complexes:

  • RAB11FIP3 indirectly interacts with rhodopsin through Rab11a and ASAP1

  • GST-pulldown assays show that RAB11FIP3 competes with rhodopsin for binding to ASAP1

  • FIP3 coordinates interactions of ASAP1 and Rab11a with Rabin8

• Immunofluorescence co-localization studies:

  • Label ciliary structures with markers such as acetylated tubulin

  • Co-stain with RAB11FIP3 antibody to visualize protein localization

  • Use confocal microscopy for high-resolution imaging

• Functional assays after RAB11FIP3 ablation:

  • Knockout/knockdown of RAB11FIP3 abolishes ciliary targeting

  • Results in rhodopsin mislocalization

  • Mimics phenotypes seen with ASAP1 deficiency

These methods have revealed that FIP3 functions as a crucial targeting regulator for ciliary receptor trafficking by facilitating the orderly assembly and activation of the Rab11-Rabin8-Rab8 cascade .

What methodological approaches are effective for studying RAB11FIP3's role in cell motility?

To investigate RAB11FIP3's function in regulating cell motility, particularly in breast cancer cells:

• Cell spreading assay:

  • Plate control or RAB11FIP3 siRNA-treated cells on collagen-coated coverslips

  • Fix cells after 1 or 3 hours

  • Stain with rhodamine-conjugated phalloidin to visualize F-actin

  • Measure cell surface area using imaging software

  • Calculate polarization by measuring the ratio between length and width

• Reverse transcriptase PCR (RT-PCR):

  • Extract total RNA using TRIzol

  • Perform reverse transcription with SuperScript III and random hexamers

  • Use specific primers for RAB11FIP3 and related genes

  • Run PCR for 40 cycles with parameters: 94°C (60s), 55°C (60s), 72°C (90s)

• Flow cytometry analysis:

  • Transfect cells with control or RAB11FIP3 siRNA

  • Analyze expression levels after 48-72 hours

  • Combine with cell surface marker analysis to assess changes in cellular phenotype

These methods have demonstrated that FIP3 plays a significant role in regulating breast cancer cell motility, with implications for metastatic potential.

How can crystallographic studies of RAB11FIP3-Rab11 interaction inform antibody epitope selection?

Crystal structure analysis of the RAB11FIP3-Rab11 complex provides critical insights for antibody design:

• The crystal structure of Rab11 in complex with the RAB11FIP3 Rab11-binding domain (RBD) has been determined at 1.75-Å resolution

• Key structural features include:

  • FIP3-RBD forms a parallel coiled-coil homodimer

  • Two Rab11 molecules bind symmetrically to the FIP3-RBD dimer

  • The hydrophobic side of the RBD helix mediates homodimerization and interacts with Rab11's switch 1 region

  • The hydrophilic side interacts with Rab11's switch 2 region and determines binding specificity

For antibody development, targeting the following regions would be most effective:

• Residues 733-756 of FIP3 (minimal RBD)

• The N-terminal region of RBD (residues 733-737) is crucial for Rab11 binding

• The C-terminal region (last 4 residues) is essential for full binding capacity

Antibodies targeting these specific regions can be used to disrupt or detect the RAB11FIP3-Rab11 interaction in various experimental contexts .

What methodological approaches can determine if RAB11FIP3 simultaneously binds Rab11 and ARF5/ARF6?

To investigate simultaneous binding of RAB11FIP3 to multiple GTPases:

• GST pulldown assays with quantitative analysis:

  • Preload GST-Rab11(Q70L) on glutathione-Sepharose beads

  • Add constant amounts of His6/T7-FIP3

  • Add varying amounts of His6/T7-ARF5(Q71L)

  • Analyze bound material by immunoblotting with anti-T7-tag antibody

  • Quantify the amount of each protein pulled down

• Co-immunoprecipitation with RAB11FIP3 antibodies:

  • Immunoprecipitate RAB11FIP3 from cell lysates

  • Probe for co-precipitated Rab11 and ARF5/ARF6

  • Perform reciprocal IPs with Rab11 and ARF antibodies

• Structural mapping:

  • Use antibodies targeting distinct domains (ABD vs. RBD)

  • Perform competitive binding assays

  • Determine if binding is mutually exclusive or compatible

Research has demonstrated that the amount of His6/T7-FIP3 and His6/T7-ARF5(Q71L) pulled down with GST-Rab11(Q70L) remains constant regardless of ARF5 concentration, suggesting independent and simultaneous binding of Rab11 and ARF5 to FIP3 . This methodological approach provides clear evidence for the dual effector role of RAB11FIP3.

How can non-specific binding be reduced when using RAB11FIP3 antibodies for immunostaining?

To minimize background and ensure specific staining:

• Optimize blocking conditions:

  • Use phosphate-buffered saline containing 0.2% bovine serum albumin and 1% fetal bovine serum

  • For high background, increase BSA concentration to 1-5%

  • Consider adding 0.1-0.3% Triton X-100 for better penetration

• Antibody titration:

  • Test multiple dilutions within the recommended range (1:50-1:500 for IHC)

  • For each new tissue type or fixation method, establish optimal concentration

• Antigen retrieval optimization:

  • Use TE buffer pH 9.0 as recommended for most tissues

  • Alternative: citrate buffer pH 6.0 for certain applications

  • Optimize retrieval time and temperature

• Validation with proper controls:

  • Include secondary antibody-only controls

  • Use tissue known to be negative for RAB11FIP3

  • Include a competition control with immunizing peptide if available

These approaches can significantly improve signal-to-noise ratio in immunostaining applications.

What strategies can resolve contradictory results when investigating RAB11FIP3 function?

When faced with inconsistent findings regarding RAB11FIP3 function:

• Validate antibody specificity:

  • Confirm antibody recognizes endogenous RAB11FIP3 at the expected molecular weight (82 kDa)

  • Use knockout/knockdown controls to verify specific detection

  • Consider using multiple antibodies targeting different epitopes

• Address cell-specific or context-dependent effects:

  • RAB11FIP3 functions differently in various cell types (neuronal, epithelial, cancer cells)

  • Document specific cell lines, culture conditions, and experimental timepoints

  • Consider the influence of cell cycle stage (especially important for cytokinesis studies)

• Evaluate potential isoform-specific effects:

  • RAB11FIP3 has functional domains for both Rab11 and ARF interactions

  • Different experimental approaches may preferentially detect specific protein complexes

  • Use domain-specific antibodies to distinguish functional pools

• Reconcile contradictory mutation studies:

  • Some studies show Y629A mutation in Rip11 abolishes Rab11 binding, while Y629F retains binding

  • Different mutations of acidic residues in various FIPs have inconsistent effects on Rab11 binding

  • These differences highlight structural nuances in FIP family proteins that may explain functional variation

By systematically addressing these factors, researchers can better understand contradictory results and develop more precise models of RAB11FIP3 function.

How can RAB11FIP3 antibodies be combined with live-cell imaging approaches?

For dynamic studies of RAB11FIP3 function in living cells:

• Indirect visualization approaches:

  • Generate RAB11FIP3-GFP/RFP fusion proteins for live tracking

  • Validate fusion protein function by rescue experiments using RAB11FIP3 antibodies

  • Use antibodies post-fixation to verify endogenous protein behavior matches tagged version

• Correlative light and electron microscopy:

  • Perform live-cell imaging of fluorescently-tagged RAB11FIP3

  • Fix cells at specific timepoints

  • Process for immunoelectron microscopy using RAB11FIP3 antibodies

  • This approach connects dynamic behavior with ultrastructural localization

• Antibody internalization techniques:

  • Conjugate cell-permeable RAB11FIP3 antibodies with fluorescent dyes

  • Monitor intracellular trafficking in real-time

  • Combine with inhibitors of trafficking pathways to dissect mechanisms

These integrated approaches provide complementary information about both the localization and function of RAB11FIP3 in membrane trafficking pathways, particularly in its roles during cytokinesis and in recycling endosomes .

What bioinformatic approaches can predict novel RAB11FIP3 interactions for antibody-based validation?

To identify and validate potential new RAB11FIP3 interaction partners:

• Sequence-based interaction prediction:

  • Use protein-protein interaction databases (STRING: 9606.ENSP00000262305)

  • Analyze conserved binding motifs across FIP family proteins

  • Predict potential interaction sites based on structural analysis

• Co-expression network analysis:

  • Analyze transcriptomic datasets for genes co-regulated with RAB11FIP3

  • Focus on endocytic pathway components and GTPase regulators

  • Prioritize candidates for experimental validation

• Structural homology modeling:

  • Use the crystal structure of RAB11FIP3-Rab11 complex as template

  • Model interactions with other GTPases or trafficking proteins

  • Identify critical residues for experimental mutation studies

• Experimental validation using antibodies:

  • Perform co-immunoprecipitation with RAB11FIP3 antibodies

  • Analyze by mass spectrometry to identify novel binding partners

  • Confirm interactions with reciprocal IPs and localization studies

This integrated approach has successfully identified interactions between RAB11FIP3 and components of vesicle trafficking pathways, including its dual role as an effector for both Rab11 and ARF5/ARF6 .